Provided by Tiger Trade Technology Pte. Ltd.

Repare Therapeutics Inc.

2.65
0.0000
Volume:- -
Turnover:3.22M
Market Cap:114.24M
PE:-1.56
High:2.65
Open:2.65
Low:2.65
Close:2.65
52wk High:2.66
52wk Low:0.8900
Shares:43.11M
Float Shares:22.72M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6944
EPS(LYR):-1.9969
ROE:-49.78%
ROA:-29.72%
PB:0.99
PE(LYR):-1.33

Loading ...

Repare Therapeutics completes acquisition and goes private

TIPRANKS
·
Jan 29

Repare Therapeutics Completes Acquisition by XenoTherapeutics

Reuters
·
Jan 29

Repare Therapeutics shareholders approve acquisition by XenoTherapeutics

TIPRANKS
·
Jan 17

Repare Therapeutics Inc. Held Shareholder Meeting

Reuters
·
Jan 17

Repare Shareholders Approve Acquisition by Xenotherapeutics, Inc.

THOMSON REUTERS
·
Jan 17

XenoTherapeutics to Acquire All Outstanding Shares of Repare Therapeutics

Reuters
·
Dec 29, 2025

U.S. Stock Movement | Repare Therapeutics (RPTX.US) Surges ~20% Pre-Market After Signing Deal with Gilead Sciences (GILD.US) for Experimental Cancer Asset

Stock News
·
Dec 24, 2025

Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment

MT Newswires Live
·
Dec 24, 2025

BRIEF-Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration

Reuters
·
Dec 24, 2025

Repare Therapeutics Shareholders to Receive Estimated $2.20 Per Share in XenoTherapeutics Deal

Reuters
·
Dec 24, 2025

Repare Therapeutics Inc - Gilead to Buy Rp-3467 From Repare for up to $30 Mln

THOMSON REUTERS
·
Dec 24, 2025

Repare Therapeutics Announces Acquisition of PolΘ Atpase Inhibitor, Rp-3467, by Gilead Sciences for up to $30 Million in Total Consideration

THOMSON REUTERS
·
Dec 24, 2025

Repare Therapeutics Chief Scientific Officer Michael Zinda Resigns

Reuters
·
Dec 20, 2025

Repare Therapeutics Inc. Announces Date for Upcoming Special Shareholder Meeting

Reuters
·
Dec 04, 2025

BRIEF-Repare Signs Support Agreements With Key Shareholders For Xenotherapeutics Deal

Reuters
·
Nov 21, 2025

Repare Therapeutics Secures Major Shareholder Support for XenoTherapeutics Deal

Reuters
·
Nov 21, 2025

Repare Therapeutics Enters Into Support and Voting Agreements With Significant Shareholders for Proposed Transaction With Xenotherapeutics, Inc.

THOMSON REUTERS
·
Nov 21, 2025

Repare Therapeutics Reports Positive Q3 2025 Results

TIPRANKS
·
Nov 20, 2025

Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value

Benzinga_recent_news
·
Nov 17, 2025

Repare Therapeutics Announces Acquisition by XenoTherapeutics

TIPRANKS
·
Nov 17, 2025